Heart Failure Clinical Trial
— DAN-PTRAIIOfficial title:
Effects of Percutaneous Transluminal Renal Angioplasty of Atherosclerotic Renal Artery Stenosis in High-Risk Patients - a Danish Nationwide Randomized Sham-Controlled Study.
NCT number | NCT05834803 |
Other study ID # | DAN-PTRAII |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | June 26, 2023 |
Est. completion date | June 1, 2027 |
The goal of this clinical trial is to document a beneficial effect of percutaneous transluminal renal angioplasty (PTRA) of atherosclerotic renal artery stenosis in high-risk patients selected according to the criteria used in the DAN-PTRA study. The main questions the trial aims to answer are if renal artery stenting compared with optimal medical treatment alone has beneficial effects on: - Blood pressure - Kidney function - Hospitalizations for heart failure
Status | Recruiting |
Enrollment | 80 |
Est. completion date | June 1, 2027 |
Est. primary completion date | June 1, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. One or more severe atherosclerotic renal artery stenoses defined as a stenosis =70% by catheter-based angiography. 2. In addition, at least one of the following high-risk clinical syndromes: 1. Resistant hypertension with average 24-hour ambulatory systolic blood pressure =150 mmHg despite =3 antihypertensive drugs including a diuretic, if tolerated, and each prescribed at optimal doses. 2. Rapidly declining kidney function with a reduction in estimated GFR of >5 mL/min per 1.73m2 per year and average 24-hour ambulatory systolic blood pressure =140 mmHg despite =3 antihypertensive drugs including a diuretic, if tolerated, and each prescribed at optimal doses. 3. Hospital admissions with acute decompensated heart failure (=2 hospitalizations for heart failure or =1 hospitalizations for sudden, "flash" pulmonary edema) with no obvious explanations such as nonadherence, left ventricular ejection fraction <40%, or valvular heart disease and average 24-hour ambulatory systolic blood pressure =140 mmHg despite =3 antihypertensive drugs including a diuretic, if tolerated, and each prescribed at optimal doses. All 24-hour ambulatory blood pressure monitorings are performed after nurse-administered medication. Exclusion Criteria: - Unable to provide informed consent. - Treatment resistant heart failure episodes presumed caused by renovascular disease. - Rapidly declining kidney function/acute kidney failure approaching the need for dialysis presumed caused by renovascular disease. - Fibromuscular dysplasia or other non-atherosclerotic renal artery stenosis known to be present prior to randomization. - Pregnancy or unknown pregnancy status in female of childbearing potential. - Kidney size <7 cm (pole to pole length) supplied by target vessel. - Previous kidney transplant. - Previous PTRA treatment. - Presence of a renal artery stenosis not amenable for treatment with a stent. Patients who are not eligible for randomization but treated with renal artery stenting outside the protocol are followed according to the DAN-PTRAII protocol in order to account for all PTRA treatments performed in Denmark in the study period. Patients treated with renal artery stenting without randomization in the study period include patients with: 1. Treatment resistant heart failure episodes presumed caused by renovascular disease. 2. Rapidly declining kidney function/acute kidney failure approaching the need for dialysis presumed caused by renovascular disease. 3. At least one of the listed high-risk clinical syndromes AND one or more significant atherosclerotic renal artery stenoses defined as a stenosis of 50-69% by catheter-based angiography with: - a mean translesional gradient of =10 mm Hg, or - a systolic translesional gradient of =20 mm Hg, or - a renal fractional flow reserve (Pd/Pa) of =0.8 |
Country | Name | City | State |
---|---|---|---|
Denmark | Aarhus University Hospital | Aarhus N | |
Denmark | Rigshospitalet | Copenhagen | |
Denmark | Odense University Hospital | Odense C |
Lead Sponsor | Collaborator |
---|---|
University of Aarhus | Aarhus University Hospital, Amsterdam UMC, Odense University Hospital, Rigshospitalet, Denmark, The Augustinus Foundation, Denmark., The Novo Nordic Foundation |
Denmark,
Reinhard M, Schousboe K, Andersen UB, Buus NH, Rantanen JM, Bech JN, Mafi HM, Langfeldt S, Bharadwaz A, Horlyck A, Jensen MK, Jeppesen J, Olsen MH, Jacobsen IA, Bibby BM, Christensen KL. Renal Artery Stenting in Consecutive High-Risk Patients With Atheros — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in 24-hour ambulatory systolic blood pressure. | Changes in 24-hour ambulatory systolic blood pressure from baseline to 6 months after renal artery stenting compared with optimal medical treatment alone in patients with 24-hour ambulatory average systolic blood pressure =150 mmHg at baseline. | 6 months after PTRA/sham | |
Secondary | Changes in kidney function. | Changes in kidney function (estimated glomerular filtration rate) from baseline to 6 months after renal artery stenting compared with optimal medical treatment alone. | 6 months after PTRA/sham | |
Secondary | Changes in antihypertensive treatment (defined daily doses). | Changes in antihypertensive treatment (defined daily doses) from baseline to 6 months after renal artery stenting compared with optimal medical treatment alone. | 6 months after PTRA/sham | |
Secondary | Changes in 24-hour ambulatory systolic blood pressure (statistically adjusted for treatment changes). | Changes in 24-hour ambulatory systolic blood pressure from baseline to 6 months after renal artery stenting compared with optimal medical treatment alone in patients with 24-hour ambulatory average systolic blood pressure =150 mmHg at baseline. Changes in systolic blood pressure will be adjusted for changes in the defined daily doses (DDD) of antihypertensive medications, where a change of 1DDD equals a change of 5 mmHg in the systolic blood pressure. | 6 months after PTRA/sham | |
Secondary | Number of participants with cardiovascular and kidney outcomes. | Clinical events included in the composite end point from baseline to 6-month follow-up:
death from cardiovascular causes death from renal causes stroke myocardial infarction hospitalization for congestive heart failure progressive renal insufficiency (a reduction from baseline of 50% or more in estimated GFR) permanent renal-replacement therapy Clinical events are defined using the same criteria as in the Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) study except for progressive renal insufficiency (in the CORAL study defined as a reduction from baseline of 30% or more in the estimated GFR). Only the first event per participant is included in the composite. |
6 months after PTRA/sham | |
Secondary | Number of deaths from any cause. | Death from any cause from baseline to 6 months after renal artery stenting compared with optimal medical treatment alone. | 6 months after PTRA/sham | |
Secondary | Health status on 12-Item Short Form Survey (SF-12). | Changes in 12-item short form health survey (SF-12) from baseline to 6 months after renal artery stenting compared with optimal medical treatment alone.
Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning. |
6 months after PTRA/sham | |
Secondary | Number of participants with procedure-related major adverse events (MAE) <30 days of PTRA/sham. | Number of participants with procedure-related MAEs including:
all cause mortality rupture, dissection, perforation or occlusion of renal artery critical bleeding (need of blood transfusion) embolization significant loss of kidney function (reduction from baseline of 50% or more in eGFR) permanent renal-replacement therapy ipsilateral nephrectomy access complications requiring treatment: bleeding, pseudoaneurysm or thrombosis stent thrombosis after renal artery stenting |
<30 days after PTRA/sham |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Active, not recruiting |
NCT05896904 -
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
|
N/A | |
Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
Recruiting |
NCT05631275 -
The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
|
||
Enrolling by invitation |
NCT05564572 -
Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology
|
N/A | |
Enrolling by invitation |
NCT05009706 -
Self-care in Older Frail Persons With Heart Failure Intervention
|
N/A | |
Recruiting |
NCT04177199 -
What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
|
||
Terminated |
NCT03615469 -
Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)
|
N/A | |
Recruiting |
NCT06340048 -
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT05679713 -
Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
|
||
Completed |
NCT04254328 -
The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure
|
N/A | |
Completed |
NCT03549169 -
Decision Making for the Management the Symptoms in Adults of Heart Failure
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05538611 -
Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
|
||
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Completed |
NCT06026683 -
Conduction System Stimulation to Avoid Left Ventricle Dysfunction
|
N/A | |
Withdrawn |
NCT03091998 -
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
|
Phase 1 | |
Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|